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OBJECTIVES: The Pharmacy and Therapeutics Committee (P&TC) is a policy recom-
mending and enforcing body which oversees the adoption of effective formulary 
system within the health care organization, the aim of the study is to explore the 
characteristics of P& TC in tertiary and secondary hospitals in Riyadh city, Saudi 
Arabia. METHODS: A cross-sectional survey targeted hospital pharmacy mangers 
in Riyadh city in 2014. The survey gathered information about P&TC organizational, 
communicational and functional characteristics. RESULTS: Of 30 hospital pharma-
cies, 23 (76.6%) pharmacy managers responded, 21(70%) hospitals met the inclu-
sion criteria, 15 (71.4%) are governmental and 6 (28.6%) are private hospitals. Of 21 
hospitals, 20 (95.2%) have P&T Committee. 15 (71.4%) committees have all required 
written policies and procedures that govern the committee business. The aver-
age total number of the P&T committee members is 13.5 (SD= 5), and dominated 
by physicians, pharmacists, and nurses (6.9 (SD= 3.4), 2.7(SD= 1.2), and 1.4(SD= 0.8)) 
respectively. 89.5% of these committees are chaired by physicians and 100% of them 
are coordinated by the pharmacists. Only 9 (45%) of the committees distribute the 
meeting agenda to their members 6 days or more before the meeting date. The 
average number of meetings is 12 (SD= 6) meeting per year, drug availability, for-
mulary change updates, drug safety related issues were frequently discussed in 
each meeting of 11(55%) hospital P&T committees. Formulary non adherence is less 
frequently, and prescribing guidelines is the least frequent. The average number of 
drugs deleted or added to the formulary are 6.3(SD= 5.9), 19.2 (SD= 18.9) drug per 
year, respectively. CONCLUSIONS: Adopting P&T Committee in Saudi governmental 
hospitals is a common practice, however, it considered in early stage in private hos-
pitals and more likely to be contributed to the accreditation requirements, therefore, 
more study to be done to study the quality of the committees in private hospital to 
ensure the effectiveness of formulary system.
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OBJECTIVES: To determine the influencing factors and main principles of regulatory 
and policy framework in the pharmaceutical wholesale and retail system to identify 
good practices for adaptation in Central Eastern European (CEE) countries. METHODS: 
A comprehensive literature review in the scientific and grey literature and a series of 
expert interviews were conducted to identify influencing factors in three major cat-
egories: general political, business economic and health policy principles. RESULTS: 
Regulatory and policy framework related to the pharmaceutical wholesale and retail 
system is influenced by multiple stakeholders with different interest. Health policy 
demands timely access to high quality medicines to maximise health gain for the 
population with respect to equity. Budget constraints necessitate public need for a 
sustainable and efficient pharmaceutical distribution channel. To overcome these 
constraints, pharmaceutical wholesalers and pharmacies have to improve operational 
efficiency by taking into account economies of scale/scope; or positive synergies of 
horizontal and vertical integration. According to general political objectives policy 
makers may choose from 1) regulated vs. liberalised system, 2) with monopolistic 
vs. competing wholesalers and community pharmacies 3) with national vs. interna-
tional, and 4) public vs. private ownership. Pharmacists may consider the provision 
of advanced health care services besides the traditional logistic activities to intensify 
professional influence on health policies. CONCLUSIONS: Evidence base of policy 
and regulatory framework related to pharmaceutical trade can be improved based 
on comprehensive review of scientific evidence on major principles to harmonise 
different objectives of stakeholders. However, publications with relevance to CEE and 
in general lower income countries are very limited.
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OBJECTIVES: To understand United States (US) payer perceptions and challenges in 
the evaluation of emerging health technologies with orphan and ultra-orphan des-
ignations. METHODS: In-depth, qualitative, one-on-one interviews were conducted 
with US payer decision makers from the RTI Health Solutions US Commercial Payer 
Advisory Panel. RESULTS: In the US, patient access to orphan and ultra-orphan 
technologies is seldom denied due to the rarity of the diseases, unmet needs, and 
lack of alternative treatments. Payers identify the biggest challenges as lack of clini-
cal and comparative efficacy data and pressures from advocacy groups, patients, 
and prescribers to fund the ever-increasing numbers of orphan and ultra-orphan 
technologies, which are often very expensive and have limited clinical evidence. 
Payers estimated that spending for orphan and ultra-orphan technologies will 
increase significantly in the next 5 years, leading to concerns over future funding 
and budgets. Payers were interested in data that could have an impact on costs, cost 
offsets, resource utilization, readmissions, and real-world outcomes in their set-
tings and patient/member populations. Payers wanted to see better-defined patient 
populations and unmet needs accompanied by well-defined treatment courses (e.g., 
when to stop treatment). Benefits of new technologies may not be captured in 
traditional health economic analyses, thus increasing uncertainty. Bridging the 
clinical evidence with other robust data will be critical, because payers will be 
passing on more risk to patients and prescribers in an effort to manage budget 
constraints. CONCLUSIONS: Payers are seeking more value-based information to 
better inform decision making in the evaluation of new orphan and ultra-orphan 
technologies. The challenge to payers lies with the value of the new technology and 
who is judging that value. Rising costs of orphan and ultra-orphan technologies will 
have more impact on market access in the future; over time there will be increasing 
resistance to high prices.
objective of this study was to assess the characteristics of the reviews performed by 
the PMPRB in the period of 1998 to 2014. METHODS: Data for all reviews performed 
by the PMPRB in the period 1998 to 2014 were derived from the PMPRB webpage. 
Descriptive analysis, and trend analysis were conducted. RESULTS: PMPRB reviewed 
a total of 1457 formulations/strengths corresponding to 689 active ingredients and 
combinations in the study period. Seventy percent of PMPRB prices were within the 
guidelines and accepted. Two percent of the prices exceeded the guidelines but did 
not trigger the criteria for commencing an investigation; however, the patentee is 
expected to decrease the price. Three percent of the National Average Transaction 
Price exceeded the Maximum Average Potential Price, which triggered the inves-
tigation criteria and the drug was reported “Under Investigation”. Four percent of 
the drug prices investigated were not excessive. One and half percent of the drug 
prices were considered excessive, and by getting to this conclusion two percent 
of patentees submitted a Voluntary Compliance Undertaking (VCU). Finally one 
and half percent of patentees did not submit a VCU and PMPRB decided that a 
patented medicine was sold at an excessive price in any market in Canada, and the 
PMPRB issued a Notice of Hearing. Drug prices that were within guidelines ranged 
from92.6% (2001 to 2004) to 95.2% (2005 to 2009) respectively. However, it decreased 
to 69.8%in 2010-2014. CONCLUSIONS: The majority of the reviews performed by 
the PMPRB concluded that the prices were not excessive.
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OBJECTIVES: At the end of 2006, there was an important reform in the Hungarian 
pharmaceutical market, including serious changes in the health insurance reimburse-
ment of medicines. The aim of our study is to analyze the changes in the Hungarian 
health insurance pharmaceutical budget between 2007-2013. METHODS: Data were 
derived from the nationwide administrative dataset of the National Health Insurance 
Fund Administration (OEP), the only health care financing agency in Hungary. We 
analyzed the changes of the health insurance pharmaceutical budget between 2007-
2013. Results are given in Hungarian Forint (HUF) and US dollars (USD). The annual 
average currency exchange rates were applied according to the data of the Central 
Bank of Hungary. RESULTS: The Hungarian pharmaceutical budget was 323.6 (2007), 
325.7 (2008), 343.2 (2009), 357.2 (2010), 376.9 (2011), 315.1 (2012) and 280.0 (2013) billion 
HUF. The average annual exchange rate between Hungarian Forint and US dollar was 
183.83 (2007), 171.80 (2008), 202.26 (2009), 208.15 (2010), 200.94 (2011), 225.37 (2012) and 
223.70 (2013), which means that Hungarian Forint significantly weakened compared 
to USD. After the changes in currency exchange rate, the Hungarian pharmaceutical 
budget measured by US dollars was 1.76 (2007), 1.90 (2008), 1.70 (2009), 1.72 (2010), 
1.88 (2011), 1.40 (2012) and 1.25 (2013) billion USD. The decrease of pharma reimburse-
ment budget from 2011 to 2013 was more significant in USD dollar (33.3 %) than in 
Hungarian Forint (25.7 %) due to the weakened Hungarian currency. CONCLUSIONS: 
Due to the reform of the whole Hungarian pharmaceutical market, the Hungarian 
health insurance pharmaceutical budget significantly changed between 2007-2013. 
This change was more remarkable in USD as the Hungarian currency weakened 
compared USD during the world economic crisis.
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OBJECTIVES: One controversial issue surrounding the Free Trade Agreement (FTA) is 
patent protection and access to medicines. The FTA necessitated changes in Peruvian 
legislation to meet requirements of the treaty. This study evaluated the impact of the 
FTA on number of brand and generic pharmaceuticals registered before and after 
the agreement and implementation of the new legislation of 2009. METHODS: Data 
from 2005 to 2013 were extracted from the database provided by the Peruvian drug 
regulatory authority, DIGEMID. The frequency and proportion of brand and generic 
products registered for the first time at DIGEMID were determined using the vari-
able ‘authorization date of first registration’. Re-registered products were determined 
using the ‘authorization and expiration date’ of registration. Products awaiting regis-
tration were determined by the variable ‘status of application’. Chi-square was used to 
assess differences in proportions. RESULTS: A total of 30,201 pharmaceutical and 913 
biologics products with a unique registration number were evaluated. The proportion 
of new registrations was 74% (n= 1789) for brand and 26% (n= 621) for generic products 
in 2005; and 80% (n= 455) for brand and 20% (n= 114) for generic products in 2013 with 
a decrease of 1,841 (76%) products after legislation. The proportion of re-registrations 
was 66% (n= 714) for brand and 34% (n= 361) for generic products in 2005 with the same 
proportions in 2013 but different frequencies (58 brand and 30 generic) with a decrease 
of 987 (92%) products after legislation. There were statistically significant differences 
between brand and generic products before and after the legislation. The proportion 
of awaiting registrations was 3 times greater for brand than for generic products 
from 2009 to 2013. CONCLUSIONS: Registration of brand products was greater than 
generic products before and after the FTA and new legislation. The frequency of new 
registrations and re-registrations decreased after 2009 but increased for products 
awaiting registration.
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comparative effectiveness and economics information to better inform decision 
making in the evaluation of new health technologies. The impact of comparative 
effectiveness research and economics on formulary decision making will likely have 
more impact in the future. If study data are to be considered valuable in supporting 
health care decision-making, the rigor, transparency, and the customer perspective 
needs to drive the study methods and designs.
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OBJECTIVES: Post-hoc subgroup analyses are still used in clinical trials of medi-
cal technologies to identify patient populations in whom greatest benefits can 
be achieved, despite this being derided as an analytical approach. Indeed, using 
post-hoc analyses, aspirin has been shown to be ineffective in acute myocardial 
infarction patients born under the star signs of Libra and Gemini (ISIS-2, 1988, 
Lancet) and endarterectomy is only efficacious in treating symptomatic steno-
sis patients born on a Monday, Wednesday, or Friday (ECST group, 1998, Lancet). 
This research aimed to determine whether National Institute of Health and Care 
Excellence (NICE) appraisal recommendations could be correlated with full moon 
dates through application of a post-hoc analysis. METHODS: All NICE final appraisal 
determinations were identified up to October 2014 from which the date and deci-
sion was extracted. Full moon dates for Manchester were extracted from www.
timeanddate.com. Statistical comparisons were performed using a Chi-squared 
test. RESULTS: 532 appraisals were identified, 408 (77%) of which were approved 
(defined as ‘recommended’ or ‘optimised’). However, among the 38 recommenda-
tions issued ±1 day of a full moon this recommendation rate significantly rose to 
89% (34/38, p< 0.05). Significantly fewer appraisals also occurred in the 14-day period 
bisected by full moons versus the 14-day period bisected by new moons (183 vs. 359, 
p< 0.0001). CONCLUSIONS: Based on our post-hoc analysis, the NICE committee are 
unduly afraid of werewolves leading them being less productive around the period 
of a full moon. However, if they are pushed to issue a final recommendation close to 
a full moon they will more likely issue a positive recommendation. As werewolves 
are afraid of running water, the feasibility of constructing a moat around the NICE 
headquarters should be explored. Alternatively, regulators and HTA bodies should 
continue to view efficacy claims on the basis of post-hoc sub-group analyses with 
great scepticism.
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OBJECTIVES: To identify the predictors of the nurses undergoing a Compliance 
Monitoring Program (CMP) for substance/drug abuse successfully and assessing the 
effect of these variables on the successful completion of program. METHODS: This 
was a retrospective cross-sectional cohort study using the de-identified data from 
the Florida Intervention Project for Nurses (IPN). Status of CMP program categorized 
as ‘completed’ and ‘Incomplete’ formed the dependent variable. The independent 
variables were characteristics of the nurses - demographic (education, marital sta-
tus), type of treatment employed, years of nursing experience, healthcare institu-
tional setting that employed the nurses, healthcare specialty of nurses, diagnostic 
and statistical manual of mental disorders (DSM-axes), lab results for presence of 
drugs, presence of substance related disorders (dependency, abuse), family history 
of biological, non-biological and mental diseases, lab test results during relapse, if 
aftercare is required at end of program, status of treatment at end of program, type 
of contract, reason for dismissal from program and whether individual treatment 
is required. Imputation procedures using the Markov chain Monte Carlo simulation 
with maximum-likelihood estimation were employed to fill missing data. Statistical 
tests included descriptive analysis including chi-square tests followed by logistic 
regression (p< 0.05). RESULTS: All independent variables except family history of 
mental diseases were found associated with the status of the CMP. The stepwise 
logistic regression yielded only nursing experience in years, type of healthcare insti-
tution, specialty, nursing license and treatment (all p< 0.0001) were found associ-
ated with the completion of the CMP at p< 0.05. CONCLUSIONS: Nursing profession 
characteristics like healthcare setting, specialty and years of experience seemed to 
have a higher association with completion of the CMP for substance abuse.
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OBJECTIVES: Since July 2012, a new therapy may be allocated Breakthrough Therapy 
status if it a) treats a serious and life-threatening condition, and b) preliminary 
evidence suggests substantial clinical improvement over existing therapies based 
on a clinically meaningful endpoint. For such agents, the FDA will expedite their 
development and review. This research aimed to systematically analyse all therapies 
have been approved under this new FDA expedited review pathway. METHODS: All 
publically available FDA documents relating to the approval of therapies under a 
breakthrough status were extracted up to 28th November 2014 and their date, drug 
type, and supportive trial package were extracted. RESULTS: The FDA has approved 
14 therapeutic agents designated as breakthrough therapies (to 1st December 2014), 
7 oncologics, 6 non-oncologics and 1 vaccine. 6/14 also simultaneously received FDA 
accelerated approval. 9 submissions were first approvals whereas 5 were line exten-
sions. 7 of these submissions were based on Phase 3 trial data, 5 on phase 2, and 2 
on phase 1 data. The average review time from submission to approval was 181 days 
(range: 126 – 242 days). There appeared no correlation between review times and 
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OBJECTIVES: The breakthrough therapy pathway provides an expedited Food and 
Drug Administration (FDA) review where preliminary clinical evidence suggests 
potentially substantial clinical improvement for a serious, life-threatening condi-
tion. This has enabled regulatory approval on data packages as early as Phase 1 data 
(ceritinib and pembrolizumab.) We wanted to research the question of whether 
such clinical data would be sufficient for US payer coverage. METHODS: On 5th 
December 2014, publically available benefits documents were extracted from 3 
national (AETNA, Anthem, and United Healthcare [UHC]) and 1 regional (Rocky 
Mountain) insurance companies for the 14 therapies approved by the FDA under 
this pathway. The coverage status, prior authorisation criteria, and price were 
compared. RESULTS: Most of the 14 FDA-approved drugs under the Breakthrough 
Therapy designation were covered by these insurers (AETNA: 10/14, UHC: 10/14, 
Anthem: 9/14, Rocky Mountain: 7/14). Most instances of drugs not covered reflect 
those approved very recently. However, the majority were subject to prior authori-
zations (AETNA: 10/10, Anthem: 9/9, UHC: 5/10, Rocky Mountain: 7/7). These prior 
authorizations sometimes included clinical criteria more stringent than those in the 
FDA label (15/31 similar to FDA label, 9/31 slightly more restrictive, 7/31 much more 
restrictive). The drugs most frequently subject to much greater restrictions than the 
FDA label were Sovaldi and Harvoni. The level of restrictions were not seemingly 
related to the patient cost per treatment which ranged up to $307,000 (Kalydeco) but 
rather seemed correlated with budget impact (very large with Sovaldi and Harvoni, 
indicated for Hepatitis C). CONCLUSIONS: Breakthrough status can result in early 
US payer approval in addition to regulatory approval. Insurers may place additional 
restrictions through prior authorizations but this relates more to the budget impact 
of the drugs than the cost per patient or level of supportive clinical evidence.
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OBJECTIVES: The US is the largest prescription drug market in the world, charac-
terised by high drug prices internationally with traditionally few price controls. 
This sustainability of the largely free-pricing of pharmaceuticals has long been 
questioned against the background of increasing pharmaceutical spend. The recent 
market entrants of innovative Hepatitis C virus (HCV) therapies with potentially 
substantial budgetary implications have driven US public and private payers to 
implement a range of cost-containment mechanisms. This research aims to com-
pare these new changes with European processes and predict how the future 
pricing and reimbursement (P&R) landscape will evolve in the US. METHODS: A 
thematic analysis of P&R changes and activities in the US December 2013-January 
2015 was undertaken, with the outcomes analysed in the context of European P&R 
processes. RESULTS: The range of novel cost-control mechanisms in the US includes 
major pharmacy benefits management organisations (CVS and Express Scripts) 
agreeing exclusivity deals with a particular HCV drug manufacturer, based on the 
most competitively priced. Further, the California Technology Assessment Forum, 
which had only previously evaluated one drug in its 13 year history, has undertaken 
already one review of HCV therapies (with another one ongoing) recommending 
restricting SOVALDI and OLYSIO to the most severe patients based on a cost-utility 
analysis. Further, under Medicaid, nearly half of all states have restricted SOVALDI 
beyond the FDA-approved label. CONCLUSIONS: Cost-control mechanisms in the US 
have started to reshape the P&R landscape with European-style price competition, 
restricting drugs to subpopulations beyond the label, and cost-effectiveness analy-
ses utilisation now starting to take hold. As pharmaceutical spend continues to grow, 
such cost-management tools will become further embedded in a wider variety of 
US payers. With variable usage of distinct cost-containment tools by different payer 
bodies, the US payer landscape will likely increasingly resemble that of Europe.
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OBJECTIVES: To identify United States (US) decision maker perceptions of data from 
observational studies and other health economics and outcomes research in the 
evaluation of emerging health technologies. METHODS: We conducted qualitative 
one-on-one interviews with payers (5), clinicians (6), and hospital administrators 
(4) in the US to determine perceptions of data collected outside of randomized con-
trolled trials in the evaluation of emerging health technologies. RESULTS: Clinical 
efficacy and safety postmarketing assessments have more of an impact on decision 
making than other types of study data collected outside clinical trials. Compared 
with other stakeholders, clinicians placed a particularly high value on patient reg-
istries, whereas, hospital administrators placed a high value on budget-impact 
analysis. Annual/semiannual review of drug classes by health plans and hospital 
formulary committees may include patient registry data; however, these data typi-
cally are not available when a new health technology is first introduced into the 
market. Real-world outcomes and head-to-head comparisons are highly desirable, 
but were also the most commonly mentioned data gaps in evaluating new health 
technologies. Clinicians more commonly sought data that affect patient treatment 
decisions, confidence in prescribing, and subpopulation data. Payers and hospital 
administrators were interested in real-world outcomes data in their specific patient 
populations, and data that could have an impact on costs, cost offsets, resource utili-
zation, and readmissions. CONCLUSIONS: Stakeholders in the US are seeking more 
